In The News: 02/08

If you suffer from rheumatoid arthritis (RA), those extra pounds could prevent you from going into remission. In a study presented during a meeting of the American College of Rheumatology in November, 100 RA patients were given combination therapy consisting of methotrexate, sulfasalazine, hydroxychloroquine, and prednisolone combined with either infliximab or a placebo. After 12 months, 58 percent of the normal-weight participants taking combination therapy and placebo were in remission, compared to 35 percent of those who were considered overweight. Excess weight, however, had little to do with the patients ability to achieve remission when taking combination therapy and infliximab. "Obesity induces resistance to conventional antirheumatic drugs," the studys authors said. "Infliximab overcomes this resistance, probably due to its direct effect on inflammatory mediators."
To continue reading this article or issue you must be a paid subscriber. Sign in

Subscribe to Arthritis Advisor

Get the next year of Arthritis Advisor for just $20. And access all of our online content - over 1,000 articles - free of charge.
Subscribe today and save 36%. It's like getting 4 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access